ReviewWorld journal of clinical oncology2020
Active surveillance in low risk papillary thyroid carcinoma.
Review in World journal of clinical oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Reply to the Letter to the Editor: Propensity-matched comparison of microwave ablation and surgical resection for preoperative T1N0M0 papillary thyroid carcinoma-5-year follow-up.European radiology · 2026Article
- Is conservative treatment always safe in unifocal clinically T1a/node-negative papillary thyroid carcinoma?World journal of surgery · 2025Article
- Thirty years of active surveillance for low-risk thyroid cancer, lessons learned and future directions.Reviews in endocrine & metabolic disorders · 2024Review
- Implementing active surveillance for low-risk thyroid carcinoma into clinical practice: collaborative recommendations for Latin America.Archives of endocrinology and metabolism · 2024Review
- Active surveillance of papillary thyroid carcinoma in Latin America: a scoping review.Archives of endocrinology and metabolism · 2024Article
- Regulatory role of Chitinase 3-like 1 gene in papillary thyroid carcinoma proved by integration analyses of single-cell sequencing with cohort and experimental validations.Cancer cell international · 2023Article
- Thyroid Microcarcinoma in Pediatric Population in Romania.Children (Basel, Switzerland) · 2021Article
- Ultrasound-Guided Radiofrequency AblationFrontiers in endocrinology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent decades, while the incidence of thyroid cancer has increased exponentially around the world, mortality has remained stable. The vast majority of this increase is attributable to the identification of intrathyroidal papillary microcarcinomas, which exhibit slow growth rates with indolent courses. A diagnosis of thyroid cancer based upon the presence of these small tumors could be considered as an overdiagnosis, as the majority of these tumors would not likely result in death if left untreated. Although surgical resection was the classical standard therapy for papillary microcarcinomas, active surveillance (AS) has emerged over the last three decades as an alternative approach that is aimed to recognize a minority group of patients who will clinically progress and would likely benefit from rescue surgery. Despite the encouraging results of AS, its implementation in clinical practice is strongly influenced by psychosocial factors. The aim of this review is to describe the epidemiology, clinical evolution, prognostic factors, and mortality of papillary thyroid microcarcinomas. We also summarize the AS strategy according to published evidence, characterize the criteria for selecting patients for AS according to risk factors and environmental characteristics, as well as analyze the current limitations for AS implementation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.